baxdrostat dapagliflozin
Sponsor Astrazeneca PLC · listed as AZN
baxdrostat dapagliflozin is a drug asset sponsored by Astrazeneca PLC, listed as AZN. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Feb 24, 2028 (day precision, medium confidence), tied to trial NCT06268873. That trial is in Phase 3 and currently active not recruiting, studying Chronic Kidney Disease and Hypertension. It appears across 3 tracked trials in the CSA sample.
Next catalyst
Trial & sponsor
Trials for baxdrostat dapagliflozin in the CSA sample
| Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|
| NCT06268873 catalyst | Phase 3 | Active, not recruiting | 2028-02-24 | Experimental | AstraZeneca | Chronic Kidney Disease and Hypertension |
| NCT06677060 | Phase 3 | Recruiting | 2029-12-17 | Experimental | AstraZeneca | Heart Failure |
| NCT06742723 | Phase 3 | Recruiting | 2029-12-18 | Experimental | AstraZeneca | Chronic Kidney Disease and Hypertension |
Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 → More AZN catalysts